{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:13:42Z","timestamp":1791353622640,"version":"4.3.1"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"CJ Martin Fellowship","award":["APP1054107"],"award-info":[{"award-number":["APP1054107"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Fluoroquinolone (FQN) therapy of latent tuberculosis infection among contacts of individuals with multidrug-resistant tuberculosis (MDR-TB) is controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the potential benefits, risks (including acquired FQN resistance), and cost-effectiveness of FQN therapy to prevent TB in contacts of individuals with MDR-TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used decision analysis to estimate costs and outcomes associated with no therapy compared with a 6-month course of daily FQN therapy to treat latent TB infection in contacts of individuals with MDR-TB. Outcomes modeled were the incidence of MDR-TB, MDR-TB with FQN resistance, TB-related death, quality-adjusted life years, and health system costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>FQN preventive therapy resulted in health system savings, lower incidence of MDR-TB, and lower mortality than no treatment. We found the incidence of MDR-TB with acquired FQN resistance would also be lower with FQN therapy of infected contacts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our model, FQN preventive therapy resulted in substantial health system savings and in reduced mortality, incidence of MDR-TB, and incidence of acquired FQN-resistant disease as well as improved quality of life. FQN therapy remained cost saving with improved outcomes even if the effectiveness of therapy in preventing MDR-TB was as low as 10%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201501-0069oc","type":"journal-article","created":{"date-parts":[[2015,4,27]],"date-time":"2015-04-27T15:47:31Z","timestamp":1430149651000},"page":"229-237","source":"Crossref","is-referenced-by-count":36,"title":["Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts: A Cost-Effectiveness Analysis"],"prefix":"10.1093","volume":"192","author":[{"given":"Gregory J.","family":"Fox","sequence":"first","affiliation":[{"name":"Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University, Montreal, Quebec, Canada; and"},{"name":"McGill International TB Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Oxlade","sequence":"additional","affiliation":[{"name":"Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University, Montreal, Quebec, Canada; and"},{"name":"McGill International TB Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[{"name":"Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University, Montreal, Quebec, Canada; and"},{"name":"McGill International TB Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,7,15]]},"reference":[{"key":"2026032100114907500_bib1","article-title":"Global tuberculosis report","author":"World Health Organization","year":"2014"},{"key":"2026032100114907500_bib2","doi-asserted-by":"crossref","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"key":"2026032100114907500_bib3","article-title":"Multidrug-resistant TB (MDR-TB)","author":"World Health Organization","year":"2013"},{"key":"2026032100114907500_bib4","doi-asserted-by":"crossref","first-page":"e54587","DOI":"10.1371\/journal.pone.0054587","article-title":"What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?","volume":"8","author":"Pooran","year":"2013","journal-title":"PLoS One"},{"key":"2026032100114907500_bib5","first-page":"1314","article-title":"Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia","volume":"11","author":"Shin","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026032100114907500_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(10)61972-1","article-title":"Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study","volume":"377","author":"Becerra","year":"2011","journal-title":"Lancet"},{"key":"2026032100114907500_bib7","first-page":"CD001363","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons","volume":"(2)","author":"Smieja","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032100114907500_bib8","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2026032100114907500_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M14-1019","article-title":"Treatment of latent tuberculosis infection: a network meta-analysis","volume":"161","author":"Stagg","year":"2014","journal-title":"Ann Intern Med"},{"key":"2026032100114907500_bib10","article-title":"Management of contacts of MDR TB and XDR TB patients","author":"European Centre for Disease Prevention and Control","year":"2012"},{"key":"2026032100114907500_bib11","doi-asserted-by":"crossref","first-page":"912","DOI":"10.5588\/ijtld.13.0028","article-title":"Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012","volume":"18","author":"Bamrah","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026032100114907500_bib12","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/cid\/cit655","article-title":"Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study","volume":"57","author":"Seddon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026032100114907500_bib13","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"2026032100114907500_bib14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1128\/AAC.00414-06","article-title":"Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy","volume":"51","author":"Shandil","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100114907500_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0962-8479(95)90001-2","article-title":"In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355)","volume":"76","author":"Saito","year":"1995","journal-title":"Tuber Lung Dis"},{"key":"2026032100114907500_bib16","first-page":"915","article-title":"Antituberculosis activity of ofloxacin (DL 8280) on experimental tuberculosis in mice","volume":"132","author":"Tsukamura","year":"1985","journal-title":"Am Rev Respir Dis"},{"key":"2026032100114907500_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/11536360-000000000-00000","article-title":"Safety profile of the fluoroquinolones: focus on levofloxacin","volume":"33","author":"Liu","year":"2010","journal-title":"Drug Saf"},{"key":"2026032100114907500_bib18","doi-asserted-by":"crossref","first-page":"e53599","DOI":"10.1371\/journal.pone.0053599","article-title":"Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review","volume":"8","author":"Langendam","year":"2013","journal-title":"PLoS One"},{"key":"2026032100114907500_bib19","author":"World Health Organization"},{"key":"2026032100114907500_bib20","author":"World Health Organization"},{"key":"2026032100114907500_bib21","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"American Thoracic Society","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"2026032100114907500_bib22","author":"Curry International Tuberculosis Center, California Department of Public Health"},{"key":"2026032100114907500_bib23","article-title":"Drug-resistant tuberculosis: a survival guide for clinicians","author":"Curry International Tuberculosis Center, California Department of Public Health","year":"2008"},{"key":"2026032100114907500_bib24","article-title":"Guidelines on the management of latent tuberculosis infection","author":"World Health Organization","year":"2014"},{"key":"2026032100114907500_bib25","author":"Howden","year":"2010"},{"key":"2026032100114907500_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1164\/rccm.200901-0146OC","article-title":"Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure","volume":"180","author":"Devasia","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100114907500_bib27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1164\/ajrccm.158.2.9801062","article-title":"Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis","volume":"158","author":"Behr","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100114907500_bib28","article-title":"Global report: UNAIDS report on the global AIDS epidemic 2012. Geneva, Switzerland: Joint United Nations Programme on HIV\/AIDS (UNAIDS)","author":"Joint United Nations Programme on HIV\/AIDS","year":"2012"},{"key":"2026032100114907500_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1164\/rccm.200901-0078OC","article-title":"Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis","volume":"180","author":"Dorman","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100114907500_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1164\/rccm.200603-360OC","article-title":"Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis","volume":"174","author":"Burman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100114907500_bib31","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/jac\/dkr281","article-title":"Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model","volume":"66","author":"Cremades","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2026032100114907500_bib32","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3201\/eid2005.131037","article-title":"Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005\u20132007","volume":"20","author":"Marks","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2026032100114907500_bib33","article-title":"American Hospital Formulary Service drug information. Bethesda, MD: American Society of Hospital Pharmacists","author":"McEvoy","year":"2014"},{"key":"2026032100114907500_bib34","article-title":"Consumer price index","author":"U.S. Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes","year":"2014"},{"key":"2026032100114907500_bib35","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the panel on cost-effectiveness in health and medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"key":"2026032100114907500_bib36","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/cid\/ciu572","article-title":"Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis","volume":"59","author":"Cegielski","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026032100114907500_bib37","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/cid\/cis978","article-title":"Direct observation therapy-plus can prevent acquired resistance to fluoroquinolones among patients with multidrug-resistant tuberculosis in Taiwan","volume":"56","author":"Chien","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026032100114907500_bib38","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3201\/eid1205.050681","article-title":"Isoniazid preventive therapy and risk for resistant tuberculosis","volume":"12","author":"Balcells","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"2026032100114907500_bib39","first-page":"180ra49","article-title":"Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis","volume":"5","author":"Mills","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026032100114907500_bib40","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","article-title":"6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial","volume":"377","author":"Samandari","year":"2011","journal-title":"Lancet"},{"key":"2026032100114907500_bib41","first-page":"431","article-title":"Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees","volume":"133","author":"Nolan","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"2026032100114907500_bib42","first-page":"1316","article-title":"Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador","volume":"14","author":"Rouzier","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026032100114907500_bib43","doi-asserted-by":"crossref","first-page":"e30194","DOI":"10.1371\/journal.pone.0030194","article-title":"Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis","volume":"7","author":"Holland","year":"2012","journal-title":"PLoS One"},{"key":"2026032100114907500_bib44","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A four-month gatifloxacin-containing regimen for treating tuberculosis","volume":"371","author":"Merle","year":"2014","journal-title":"N Engl J Med"},{"key":"2026032100114907500_bib45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijid.2014.03.1388","article-title":"Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates","volume":"26","author":"Ho","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2026032100114907500_bib46","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1086\/379328","article-title":"Fluoroquinolone resistance in patients with newly diagnosed tuberculosis","volume":"37","author":"Ginsburg","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2026032100114907500_bib47","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1164\/rccm.201406-1159OC","article-title":"Risk of tuberculosis after recent exposure: a 10-year follow-up study of contacts in Amsterdam","volume":"190","author":"Sloot","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100114907500_bib48","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1164\/ajrccm\/137.4.805","article-title":"Tuberculosis in a cohort of Southeast Asian Refugees: a five-year surveillance study","volume":"137","author":"Nolan","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"2026032100114907500_bib49","first-page":"572","article-title":"Tuberculosis morbidity in the U.S. Navy: its distribution and decline","volume":"110","author":"Comstock","year":"1974","journal-title":"Am Rev Respir Dis"},{"key":"2026032100114907500_bib50","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/oxfordjournals.aje.a112105","article-title":"Frost revisited: the modern epidemiology of tuberculosis","volume":"101","author":"Comstock","year":"1975","journal-title":"Am J Epidemiol"},{"key":"2026032100114907500_bib51","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis: a general review","volume":"26","author":"Ferebee","year":"1970","journal-title":"Bibl Tuberc"},{"key":"2026032100114907500_bib52","first-page":"1","article-title":"United States life tables, 2009","volume":"62","author":"Arias","year":"2014","journal-title":"Natl Vital Stat Rep"},{"key":"2026032100114907500_bib53","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.5588\/ijtld.13.0095","article-title":"Cost-effectiveness of Xpert\u00ae MTB\/RIF for diagnosing pulmonary tuberculosis in the United States","volume":"17","author":"Choi","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026032100114907500_bib54","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1524-4733.2008.00355.x","article-title":"Health state utilities in latent and active tuberculosis","volume":"11","author":"Guo","year":"2008","journal-title":"Value Health"},{"key":"2026032100114907500_bib55","article-title":"Reported tuberculosis in the United States 2013","author":"Centers for Disease Control and Prevention","year":"2014"},{"key":"2026032100114907500_bib56","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09031936.00134712","article-title":"Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes","volume":"42","author":"Falzon","year":"2013","journal-title":"Eur Respir J"},{"key":"2026032100114907500_bib57","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","article-title":"Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial","volume":"373","author":"Conde","year":"2009","journal-title":"Lancet"},{"key":"2026032100114907500_bib58","first-page":"163","article-title":"Current management options for latent tuberculosis: a review","volume":"5","author":"Norton","year":"2012","journal-title":"Infect Drug Resist"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/192\/2\/229\/67284258\/ajrccm_192_2_229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/192\/2\/229\/67284258\/ajrccm_192_2_229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:11:57Z","timestamp":1774066317000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/192\/2\/229\/8504654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,7,15]]},"published-print":{"date-parts":[[2015,7,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201501-0069oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,7]]},"published":{"date-parts":[[2015,7]]}}}